2nd Annual EGFR Resisters Research Summit
cece2020-10-22T14:53:03-07:00Save the Date: Virtual Meeting - November 12-14, 2020 We are very excited to announce that the EGFR Resisters will
22 October 2020
16 October 2020
Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC
laurabbook@gmail.com2020-10-16T12:53:20-07:00*September 2020* Note: this is in context of HER2, another resistance mechanism of EGFR TKIs. Trastuzumab deruxtecan has demonstrated impressive
16 October 2020
First Drug for MET+ NSCLC Shows High Response Rates
laurabbook@gmail.com2020-10-16T12:48:59-07:00*September 2020* The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta),
16 October 2020
Drug Active in ‘Undruggable’ KRAS-Mutant NSCLC
laurabbook@gmail.com2020-10-16T12:44:07-07:00*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients
16 October 2020
BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models
laurabbook@gmail.com2020-10-16T12:38:36-07:00*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance
16 October 2020
Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer
laurabbook@gmail.com2020-10-16T12:32:13-07:00*September 2020* The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had
16 October 2020
EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC
laurabbook@gmail.com2020-10-16T12:27:47-07:00*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve
16 October 2020
First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC
laurabbook@gmail.com2020-10-16T12:19:38-07:00*September 2020* Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment
16 October 2020
Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer
laurabbook@gmail.com2020-10-16T12:07:56-07:00*September 2020* Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical
16 October 2020
FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC
laurabbook@gmail.com2020-10-16T12:03:48-07:00*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment